Unlike most weight loss treatments, CBL-514 is described as making fat cells die off rather than shrink. Early clinical results are reported as encouraging.
Recap by typeshit. Post by @medicine_today_net on Instagram.
She describes MOTS-c as a messenger made by mitochondria that may help muscles handle sugar. The framing is hers and not an established health claim.
Medscape covers research tying GLP-1 drug use to lower alcohol consumption. Tap through for the study details and what researchers found.
In a small 2022 trial, whey beat leucine-boosted collagen for muscle growth, while evidence that collagen prevents sports injuries is still missing.
A retrospective study in Cureus looks back at how well once-weekly semaglutide worked, and how safe it was, for teenagers with obesity.
A sponsored-style look at compounded tirzepatide and semaglutide through telehealth firm Mochi Health, noting compounded drugs aren't FDA approved for safety or quality.
BigGo Finance reports women in the CagriSema trial lost more weight than the study population as a whole.
Loading…